vs
ESTABLISHMENT LABS HOLDINGS INC.（ESTA）与MESA LABORATORIES INC（MLAB）财务数据对比。点击上方公司名可切换其他公司
MESA LABORATORIES INC的季度营收约是ESTABLISHMENT LABS HOLDINGS INC.的1.0倍（$65.1M vs $64.6M），ESTABLISHMENT LABS HOLDINGS INC.同比增速更快（45.2% vs 3.6%），MESA LABORATORIES INC自由现金流更多（$18.0M vs $-2.0M），过去两年ESTABLISHMENT LABS HOLDINGS INC.的营收复合增速更高（31.9% vs 5.1%）
Establishment Labs Holdings Inc.是一家总部位于美国的无晶圆厂半导体企业，同时专注于人工智能领域业务，核心为数据中心及AI基础设施研发高速连接解决方案，于2024年3月在纳斯达克挂牌上市。
梅萨实验室有限公司开发、生产和销售专业质控、校准及监测仪器与配套服务，核心业务覆盖医疗健康、制药、食品饮料、工业卫生及环境检测领域，为全球客户满足合规及运营安全需求提供支持。
ESTA vs MLAB — 直观对比
营收规模更大
MLAB
是对方的1.0倍
$64.6M
营收增速更快
ESTA
高出41.5%
3.6%
自由现金流更多
MLAB
多$20.0M
$-2.0M
两年增速更快
ESTA
近两年复合增速
5.1%
损益表 — Q4 FY2025 vs Q3 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $64.6M | $65.1M |
| 净利润 | — | $3.6M |
| 毛利率 | 70.5% | 64.2% |
| 营业利润率 | -6.1% | 12.2% |
| 净利率 | — | 5.6% |
| 营收同比 | 45.2% | 3.6% |
| 净利润同比 | — | 316.6% |
| 每股收益（稀释后） | $-0.07 | $0.65 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ESTAMLAB
| Q4 25 | $64.6M | $65.1M | ||
| Q3 25 | $53.8M | $60.7M | ||
| Q2 25 | $51.3M | $59.5M | ||
| Q1 25 | $41.4M | $62.1M | ||
| Q4 24 | $44.5M | $62.8M | ||
| Q3 24 | $40.2M | $57.8M | ||
| Q2 24 | $44.1M | $58.2M | ||
| Q1 24 | $37.2M | $58.9M |
净利润ESTAMLAB
| Q4 25 | — | $3.6M | ||
| Q3 25 | $-11.1M | $2.5M | ||
| Q2 25 | $-16.6M | $4.7M | ||
| Q1 25 | $-20.7M | $-7.1M | ||
| Q4 24 | — | $-1.7M | ||
| Q3 24 | $-16.7M | $3.4M | ||
| Q2 24 | $-17.2M | $3.4M | ||
| Q1 24 | $-16.2M | $-254.6M |
毛利率ESTAMLAB
| Q4 25 | 70.5% | 64.2% | ||
| Q3 25 | 70.1% | 61.5% | ||
| Q2 25 | 68.8% | 62.0% | ||
| Q1 25 | 67.2% | 61.8% | ||
| Q4 24 | 68.5% | 63.3% | ||
| Q3 24 | 63.9% | 61.3% | ||
| Q2 24 | 65.6% | 64.0% | ||
| Q1 24 | 65.6% | 62.1% |
营业利润率ESTAMLAB
| Q4 25 | -6.1% | 12.2% | ||
| Q3 25 | -7.5% | 7.8% | ||
| Q2 25 | -27.5% | 5.1% | ||
| Q1 25 | -41.0% | 2.4% | ||
| Q4 24 | -41.9% | 9.2% | ||
| Q3 24 | -32.7% | 6.1% | ||
| Q2 24 | -21.2% | 9.6% | ||
| Q1 24 | -23.8% | -460.6% |
净利率ESTAMLAB
| Q4 25 | — | 5.6% | ||
| Q3 25 | -20.7% | 4.1% | ||
| Q2 25 | -32.3% | 8.0% | ||
| Q1 25 | -50.1% | -11.4% | ||
| Q4 24 | — | -2.7% | ||
| Q3 24 | -41.5% | 5.9% | ||
| Q2 24 | -38.9% | 5.8% | ||
| Q1 24 | -43.6% | -432.2% |
每股收益（稀释后）ESTAMLAB
| Q4 25 | $-0.07 | $0.65 | ||
| Q3 25 | $-0.38 | $0.45 | ||
| Q2 25 | $-0.57 | $0.85 | ||
| Q1 25 | $-0.70 | $-1.30 | ||
| Q4 24 | $-1.21 | $-0.31 | ||
| Q3 24 | $-0.59 | $0.63 | ||
| Q2 24 | $-0.62 | $0.62 | ||
| Q1 24 | $-0.58 | $-47.26 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $75.6M | $29.0M |
| 总债务越低越好 | — | $68.4M |
| 股东权益账面价值 | $23.5M | $186.7M |
| 总资产 | $357.2M | $434.8M |
| 负债/权益比越低杠杆越低 | — | 0.37× |
8季度趋势，按日历期对齐
现金及短期投资ESTAMLAB
| Q4 25 | $75.6M | $29.0M | ||
| Q3 25 | $70.6M | $20.4M | ||
| Q2 25 | $54.6M | $21.3M | ||
| Q1 25 | $69.2M | $27.3M | ||
| Q4 24 | $90.3M | $27.3M | ||
| Q3 24 | — | $24.3M | ||
| Q2 24 | — | $28.5M | ||
| Q1 24 | — | $28.2M |
总债务ESTAMLAB
| Q4 25 | — | $68.4M | ||
| Q3 25 | — | $69.4M | ||
| Q2 25 | — | $70.3M | ||
| Q1 25 | — | $71.3M | ||
| Q4 24 | $0 | $72.2M | ||
| Q3 24 | — | $73.1M | ||
| Q2 24 | — | $74.1M | ||
| Q1 24 | — | — |
股东权益ESTAMLAB
| Q4 25 | $23.5M | $186.7M | ||
| Q3 25 | $16.4M | $178.5M | ||
| Q2 25 | $22.8M | $172.5M | ||
| Q1 25 | $38.5M | $159.8M | ||
| Q4 24 | $53.1M | $155.2M | ||
| Q3 24 | $32.7M | $161.5M | ||
| Q2 24 | $45.0M | $150.7M | ||
| Q1 24 | $56.9M | $145.4M |
总资产ESTAMLAB
| Q4 25 | $357.2M | $434.8M | ||
| Q3 25 | $338.9M | $430.4M | ||
| Q2 25 | $329.7M | $435.7M | ||
| Q1 25 | $333.4M | $433.3M | ||
| Q4 24 | $346.8M | $433.3M | ||
| Q3 24 | $282.7M | $454.1M | ||
| Q2 24 | $285.1M | $440.4M | ||
| Q1 24 | $301.8M | $446.8M |
负债/权益比ESTAMLAB
| Q4 25 | — | 0.37× | ||
| Q3 25 | — | 0.39× | ||
| Q2 25 | — | 0.41× | ||
| Q1 25 | — | 0.45× | ||
| Q4 24 | 0.00× | 0.47× | ||
| Q3 24 | — | 0.45× | ||
| Q2 24 | — | 0.49× | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-162.0K | $18.8M |
| 自由现金流经营现金流 - 资本支出 | $-2.0M | $18.0M |
| 自由现金流率自由现金流/营收 | -3.1% | 27.7% |
| 资本支出强度资本支出/营收 | 2.8% | 1.1% |
| 现金转化率经营现金流/净利润 | — | 5.17× |
| 过去12个月自由现金流最近4个季度 | $-56.9M | $37.9M |
8季度趋势，按日历期对齐
经营现金流ESTAMLAB
| Q4 25 | $-162.0K | $18.8M | ||
| Q3 25 | $-11.3M | $8.2M | ||
| Q2 25 | $-18.8M | $1.9M | ||
| Q1 25 | $-20.7M | $12.7M | ||
| Q4 24 | $-20.7M | $18.1M | ||
| Q3 24 | $-12.5M | $5.3M | ||
| Q2 24 | $-14.2M | $10.7M | ||
| Q1 24 | $-11.2M | $12.9M |
自由现金流ESTAMLAB
| Q4 25 | $-2.0M | $18.0M | ||
| Q3 25 | $-13.1M | $7.1M | ||
| Q2 25 | $-20.4M | $884.0K | ||
| Q1 25 | $-21.5M | $11.9M | ||
| Q4 24 | $-21.3M | $17.3M | ||
| Q3 24 | $-13.9M | $3.5M | ||
| Q2 24 | $-15.0M | $9.9M | ||
| Q1 24 | $-14.5M | $12.3M |
自由现金流率ESTAMLAB
| Q4 25 | -3.1% | 27.7% | ||
| Q3 25 | -24.4% | 11.7% | ||
| Q2 25 | -39.7% | 1.5% | ||
| Q1 25 | -51.9% | 19.2% | ||
| Q4 24 | -47.8% | 27.6% | ||
| Q3 24 | -34.6% | 6.0% | ||
| Q2 24 | -33.9% | 16.9% | ||
| Q1 24 | -38.9% | 21.0% |
资本支出强度ESTAMLAB
| Q4 25 | 2.8% | 1.1% | ||
| Q3 25 | 3.4% | 1.8% | ||
| Q2 25 | 3.2% | 1.7% | ||
| Q1 25 | 1.8% | 1.2% | ||
| Q4 24 | 1.2% | 1.3% | ||
| Q3 24 | 3.7% | 3.1% | ||
| Q2 24 | 1.8% | 1.5% | ||
| Q1 24 | 8.9% | 0.9% |
现金转化率ESTAMLAB
| Q4 25 | — | 5.17× | ||
| Q3 25 | — | 3.32× | ||
| Q2 25 | — | 0.40× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 1.54× | ||
| Q2 24 | — | 3.17× | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ESTA
暂无分部数据
MLAB
| Sterilization And Disinfection Control | $24.9M | 38% |
| Biopharmaceutical Development | $14.4M | 22% |
| Other | $14.1M | 22% |
| Clinical Genomics | $11.8M | 18% |
